Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Oriola-KD Oyj, Q3'24

By Inderes10/30/2024, 8:00 AM
Oriola

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Dennis O'Neill
00:00 - 01:01

Good morning everyone, and a warm welcome to the Oriola Corporation Q3 results webcast. My name is Dennis O'Neill and I'm from Oriola Corporation Investor Relations. With me today, I have CEO Katarina Gabrielsson and our new CFO, Mats Danielsson. After the presentations, we will open up the Q&A and we ask you to send in your questions through the chat during the presentation. Also, as a reminder, in the Q&A we will focus on the questions about Aureolus business and financial performance. The webcast will be recorded, and the recording will be available on our website later today. Without further ado, let's go to the disclaimer. So here it is. And now, Katarina, please go ahead. Thank you, Tomas, and a warm welcome also on my behalf. This is the agenda for today. It's quite traditional. We will start.

Katarina Gabrielsson
01:01 - 08:46

With the highlights and operating environment, the segments, and then for the first time in this session, you will meet our CFO for the Financial Review. Before we go to the Q&A, if we then start with how quarter three has been going overall, I'm really happy to announce that we have improved the profitability compared to a year ago. The net sales were €424 million, which is up 19%. If we look at organic growth, it's 5%, which is due to a change from consignment stock to inventory stock. In one of the pharmaceutical companies, the adjusted EBIT was €5.5 million, and that's a growth of 25%. Adjusted EBIT, excluding the Svensk dos AB, Sweden, was €5.4 million. The net sales growth was driven by the distribution segment, which is also the reason why profitability has improved. So the net sales growth and the lower freight cost are the reasons for the improvement in profitability. The main reason the refined strategy was launched was one year ago. We announced it during the webcast a year ago, and we can see steady progress towards the goals in the strategy. I will also mention that even though we have seen changes in the management team during the third quarter, the management team is fully committed to the strategy and the long-term goals that we have for the company. A really important part of the refined strategy is the ERP project, which is proceeding according to plan. We have in the quarter renewed and harmonized the processes, and we are now in the end phase of finalizing this project phase. And then, of course, starting the build process in the joint venture company Kronans Apotek, we can see that e-commerce sales were growing by double digits, and that's improving the e-commerce footprint in Sweden. In Sweden, this is really important since we know that the e-commerce segment is very large. In Sweden, it's around 25% of the total pharmacy market. Pharmacy market in the pharmaceutical pharmacies. We can see that the volumes were relatively flat. And that has resulted in flat sales compared to a year ago. Then, going to the operating environment, the overall operating environment has stabilized. We can see that consumer confidence in Sweden is at a more normal level than in Finland, where it's a little bit weaker. The cost inflation, which mainly affects Oriola due to energy and fuel prices, has slowed down and normalized during the quarter. We can also see that this is most likely what will happen in the quarter. Challenges in the availability of pharmaceuticals continue in both Sweden and Finland, as well as in Europe, and this is also something that we predict will continue for the ongoing quarter. The pharmaceutical distribution market is continuing with steady growth, driven mainly by a strong demand in high-value pharmaceuticals. This is a trend that we have seen. And we can also, in this case, see that this is something that will continue in the future. Then, going to our segments. Let's start with the distribution segment. In Finland, we can see a stable market share but a small decline in Sweden. Net sales grew by 23% in this segment to €3,351 million, and that represents a 23% growth. And like I said before, this is because of a customer shifting from consignment stock to inventory stock. And that means that organic growth was 5%. We have higher market volumes and also price increases. That is what is supporting the organic growth. The profitability improved in this segment by 46%, with adjusted EBIT reaching €5 million compared to €3.5 million a year ago. And like I already stated, mainly depending on net sales growth and also lower costs year on year. I'm really pleased to see that we are also now building for the future in this segment. During the quarter, we have signed new and also renewed existing distribution agreements, and that will be visible also for the future quarters to come. And since we have in the strategy that we will work more cross-market, I'm also really pleased to see that we, during the quarter, have signed a cross-market customer with volumes that will start during quarter 1 in 2025. In Sweden, we have entered a new sales channel, and that's the optician channel. And that also provides opportunities for the wholesale segment. Since we have quite a few products in the wholesale segment, there is also a possibility to sell in this new channel. Then going to the wholesale segment. Wholesale segment is then consisting of the traded goods, the OTC products, the parallel import and the specialized medicines, as well as the advisory services that we then have in Oriola's portfolio. The long-term strategic goal is to grow the wholesale business in this segment. The net sales were flat at €74 million, and the profitability was also at last year's level. We can see that the Finnish wholesale business was stable, but the volumes in Sweden were declining. We are in this segment now, building for the future, and also in this segment I can see that we have added new products and suppliers to the portfolio, something that we will build on for the future. We will also gain new listings. And that means that we have new products coming into the customer portfolio, and we have also introduced new products in the Finnish market. In Sweden, I'm really pleased to see that the Dexal brand has now been introduced, and that's the first time that we can see that we are taking some products from Finland and introducing them to Sweden, and that is then one part really important for the strategic growth in this segment. A year ago, we also announced that we should sell all shares in Svensk dos AB to Apotekstjänst Sverige AB. We signed that contract in October 2023. And I think all of you also remember that during the spring, we announced that the Swedish Competition Authority had announced that the sale to Apotekstjänst Sverige AB was prohibited due to negative effects on market competition. It has also been announced that Apotekstjänst Sverige AB has appealed this decision, and during the autumn there has been an ongoing process for which we are awaiting the outcome in November. And this means that we will come back to this, of course, when we know more about the outcome. I will also tell you here now that there is one more instance to which you can appeal. So it might be that we will take a little bit longer before we have really finalized this process. Oriola is still committed to selling this business to Apotekstjänst Sverige AB, but at the same time, we are also considering other options if we receive a negative verdict from the appeals. But we will be exiting the Swedish dose dispensing business because we still see that the tender market structure and dynamics in Sweden haven't changed. With this, I will then turn over to Mats and the financial view. So, welcome Mats.

Mats Danielson
08:49 - 18:24

Thank you, Katarina. And also from my side. Good morning and welcome to this presentation. My name is Mats Danielson. Started at Oriola in mid September. I have a background in finance. Worked in different companies, different industries, and as a CFO of Oriola. I will support and drive the strategic agenda that was set and communicated already a year ago. But let's move to quarter three. If we look at net sales, we had an organic growth of 5%. If we look at the growth in the distribution segment, we see a significant increase. And that's, as Katarina also mentioned. It's mostly due to the fact that a customer has moved from consignment stock to inventory. If we look at the wholesale segment, the development is flat. We have seen a small decline in volumes in Sweden, compensated by other areas, so the total development is flat and the net sales increase is 19%. Looking at the adjusted EBIT going from 4.4 million to 5.5 million, we had the biggest increase in distribution of 1.6 million, of which 0.8 million is actually the increase from Svensk dos AB, and the rest is related to lower freight costs and other costs, and also an increase in volume. Wholesale is flat and there is a 25% increase in adjusted EBIT. Looking at the year-to-date numbers in invoicing, e-invoicing increased by 6%. Net sales again have to take into account the move from consignment to inventory. 12% increase and then the adjusted EBIT. Year to date is increasing from 11.3 last year to 15.3 this year, a 4 million increase. Svensk dos AB is 2 million. Svensk dos AB is not. So, Svensk dos AB's profitability is improving. We have lowered the cost and kept it at a level where we are not making a loss. So that's the big change. Then, the other 2 million is mostly related to lower costs and increased volume. Now also good to mention the adjusted items that we are calculating. During the autumn, we analyzed the appropriate accounting treatment of the ERP project, which is a cloud-based arrangement. And now we have decided that the cost will be booked as expenses. Mostly, we are estimating that, out of the 35 million we have estimated the total project to be, around 90% will be expenses in adjusted items and 10% will be capitalized. We have now also, due to the fact that we have changed the principles from last year, accounted for an impairment of 1.9 million as a cost in quarter three of the ERP investment, and the adjusted items in the footnote also amount to 4.4 million. So out of that, 1.9 million is actually related to last year. Looking at the distribution segments, the share of net sales is 81%. The share of adjusted EBIT is 64%. If we look at the adjusted EBIT here, we have 2 million. Year to date, Svensk dos AB has lower freight costs, other costs, and volume affecting. And we have an EBIT margin, adjusted EBIT margin of 1.3% in the distribution segment. Looking at the wholesale segment, it is important to note that the share of net sales is 19%. The share of adjusted EBIT is 6%. If we look at the net sales, it was flat in the third quarter. It's important to note that we have conducted numerous activities in Finland. There have been new listings, new products, and in Finland, there is a quite stable underlying volume. In Sweden, we introduced Dexal, which experienced a small decline in volumes that also affected the total net sales growth. Year to date and also has an impact on the adjusted EBIT. If we look at the year-to-date figures, we're going from 7.1 to 7.5 million. It's important to note that we have an adjusted EBIT margin of 3.2% in the wholesale segment. Then we go to the net profit. There was an improvement in the net profit. Last year, we had an impairment write-down in Sweden, which impacted, of course, the EBIT. We now have the financial income and expenses. The boxes are of very different sizes. The numbers are quite the same. But we have repaid debt. But that is not really seen in the numbers yet. But that will come because it has already been done. The phasing will show that there is an opportunity to reduce that a bit. At the same level as last year, we have incurred a bigger loss in the joint venture, which has affected our net profit compared to last year. So, -2.3 this year, 17.9 last year. Looking at the cash flow here, we also see that there has been a slightly improved effect from working capital this year compared to last year. We have repaid debt of 39 million this year, which has, of course, affected the cash flow. We have paid a bit more dividends than last year, and we are ending up at 83.9 million in cash. And we have an operative cash flow that is slightly positive. Looking at the net debt, still at a low level, we have repaid $51.9 million of debt during the last 12 months, and currently have a cash balance of $83.9 million. We consider that to be quite a good level, taking into consideration the fluctuations in the working capital that we have. Financial position. No significant changes in gearing and equity ratio during the quarter. Kronans Apotek has had a difficult year. The third quarter has been a bit better. If you look, the adjusted EBIT has been positive. Kronans Apotek is a very important strategic partner for us, and Kronans Apotek expects to reach the synergies of the 25 million mentioned earlier, but the integration process has been more complex than expected, especially related to the ERP integration. And that will therefore take a longer time than originally anticipated. The outlook. Outlook. We are. We are keeping the outlook and expect the adjusted EBIT to increase from the adjusted EBIT for 2023. That was 19.5 million. Thank you.

Katarina Gabrielsson
18:28 - 19:15

Then, looking at the key takeaways that we want you to remember from this presentation, you can say that I'm really happy to see that we have improved profitability in this quarter. We have also shown solid performance year over year and year to date. And we have also continued keeping the guidance. I also really want to make sure for all of you that we, as the management, are truly committed to delivering the strategy that we announced a year ago. And we are progressing towards the long-term goals that we have with full commitment, even though there have been changes in the management team. So, these are the key takeaways. And with that, I will say that we can now proceed to the questions. Great.

Dennis O'Neill
19:15 - 20:10

Thank you, Katerina and Mats, for your presentations. We have a few questions on the chat. Let's start with those. And just a reminder to everyone that please keep on sending the questions throughout the chat and also that we will focus on the questions about Oriola's business and financial development and questions relating to Kronans Apotek. We will answer, but only within a limited scope. So the first question that we have is related. Or there are a couple of questions relating to the ERP. So I think these questions will come to you. So why were the ERP-related costs so high compared to Q2, and should we expect similar levels going forward?

Mats Danielson
20:11 - 20:32

As mentioned, in the third quarter, there was 1.9 million. That was actually an effect of last year's figures, which were booked as investment or capital expenditure last year but are now recorded as a cost according to the new principles. How we are going to book the ERP costs.

Dennis O'Neill
20:34 - 20:54

Okay. And then, really following up on this one, I think you mentioned this already during the presentation, but I think it's good to repeat it. You have previously reported that one third of the total ERP costs will be handled in the P&L and the rest on the balance sheet. Is this still valid?

Mats Danielson
20:55 - 21:33

We have now analyzed the agreements we have, discussed them thoroughly, and concluded that it is a cloud arrangement. And then, therefore, we need to book all those costs not as capital expenditure, but as expenses. And there will be a small part, about 10%, that we will be able to book as capital expenditure, mostly related to on-premise applications that we will build on the ERP.

Dennis O'Neill
21:35 - 21:59

Good, thanks. And then there's a question relating to the dividend. So Oriola Corporation has previously stated that about two-thirds of net profit will be paid as dividends. What is the net profit from which this ratio is calculated, given that Oriola reports several net profit figures.

Katarina Gabrielsson
22:02 - 22:18

That's a good question, and I don't remember exactly right now, but let's come back with that one and answer it in a proper way. So we don't say the wrong thing. Because I agree, there are a lot of different figures. Let's also make it easier for everyone to understand how we calculate things in the future. Right?

Dennis O'Neill
22:18 - 22:37

Thank you. And then there is a question on the Kronans Apotek synergies. So, regarding Kronans Apotek, does your comment imply that full synergies will be realized later than the previously communicated end of 2025?

Katarina Gabrielsson
22:38 - 22:55

Overall, you can say that we are still projecting €25 million in synergies to be realized by the end of 2025. We are somewhat delayed in the overall implementation with Cronos, but we have not indicated otherwise; the target is still the end of 2025.

Unknown 1
22:55 - 22:56

Okay.

Dennis O'Neill
22:56 - 23:06

Good. Thank you. And then a couple more questions. So why didn't the good sales growth show in your profitability or market share?

Katarina Gabrielsson
23:09 - 23:09

You or me?

Mats Danielson
23:10 - 23:41

Yeah. The sales are partly, or a significant part of that is related to the transition from consignment stock to inventories. Such a change has quite a few implications because it's a kind of new contract. And so you cannot directly say that a change like this would impact profitability in a certain way. There are balance sheet effects and there are income statement effects resulting from changes in the arrangement.

Dennis O'Neill
23:41 - 23:51

Okay. Thank you. And then following up on the market share in Sweden. So you say that it dropped a little bit. So why is that?

Katarina Gabrielsson
23:51 - 24:10

Overall, you can say that there are changes in the market share, as we mentioned earlier; specifically, there are some segments in Sweden that are growing. One of them is the weight loss segment. And Oriola Corporation doesn't have this kind of portfolio in Sweden. And that means, of course, when that is growing, we are dropping a little bit.

Dennis O'Neill
24:11 - 24:24

Okay. Thank you. And then let's take the last questions about the guidance. So, what is your confidence level in reaching that in Q4?

Katarina Gabrielsson
24:25 - 25:16

Overall, you can say that we now know quite a bit about what will happen in quarter four. Like I said, when we consider the freight costs, energy costs, cost inflation, and all these factors, we can see that they are moving to a more favorable level. With that said, we can see that over the years, quarter four has consistently been the strongest quarter for us. I can also add that December might be the month when we can foresee potential outcomes, if I may put it that way. Because December this year has only 17 working days, which is fewer than we had in previous years. So that can be a warning. But we are so far into the quarter now, so I'm quite confident to say that the guidance should be there unless something really bad happens.

Dennis O'Neill
25:16 - 25:53

Okay, great. So there are no more questions at this point. And so we can end the webcast for today. And if there's anything you want to follow up on later, please don't hesitate to reach out to us. But otherwise, I would like to thank everyone for joining us today and remind you that the next webcast will be on the 4th of March, a bit later than we have had before. Before. And that's when we will come out with the full-year results. So, thank you and have a good rest of the day.

Katarina Gabrielsson
25:53 - 25:55

Thank you. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…